<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang H</submitter><funding>the 2021 Shandong Provincial Key R&amp;D Program (Major Technological Innovation Project) project</funding><funding>Yangling Demonstration Zone Seed Incubation Project</funding><funding>the Key R&amp;D Projects of Ningxia Hui Nationality Autonomous Region in 2022</funding><funding>the High-Level Talent Initiation Project of Guizhou Medical University (J [2022] 051).</funding><pagination>25</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9950318</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Cancer cells require a supply of amino acids, particularly essential amino acids such as branched-chain amino acids (BCAAs, i.e., valine, leucine, and isoleucine), to meet the increased nutrient demands of malignant tumors. The cell-autonomous and non-autonomous roles of altered BCAA supply have been implicated in cancer progression. The critical proteins involved in BCAA uptake, transport, metabolism, etc. serve as potential therapeutic biomarkers in human cancers. Here, we summarize the potential anti-tumor mechanism of BCAA by exploring the chain reaction triggered by increased BCAA supply in the tumor.&lt;h4>Method&lt;/h4>A system-wide strategy was employed to provide a generic solution to establish the links between BCAA and cancer based on comprehensive omics, molecular exp</pubmed_abstract><journal>Discover oncology</journal><pubmed_title>High dose isoleucine stabilizes nuclear PTEN to suppress the proliferation of lung cancer.</pubmed_title><pmcid>PMC9950318</pmcid><funding_grant_id>2022-JSCY-06</funding_grant_id><funding_grant_id>2022ZDYF0410</funding_grant_id><funding_grant_id>2021CXGC010509</funding_grant_id><funding_grant_id>J [2022] 051</funding_grant_id><pubmed_authors>Zhou L</pubmed_authors><pubmed_authors>Zhang F</pubmed_authors><pubmed_authors>Kang W</pubmed_authors><pubmed_authors>Ding B</pubmed_authors><pubmed_authors>Guo Z</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Zhang N</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Luo H</pubmed_authors><pubmed_authors>Cui S</pubmed_authors><pubmed_authors>Zhao Z</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Wang M</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Chen S</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors></additional><is_claimable>false</is_claimable><name>High dose isoleucine stabilizes nuclear PTEN to suppress the proliferation of lung cancer.</name><description>&lt;h4>Purpose&lt;/h4>Cancer cells require a supply of amino acids, particularly essential amino acids such as branched-chain amino acids (BCAAs, i.e., valine, leucine, and isoleucine), to meet the increased nutrient demands of malignant tumors. The cell-autonomous and non-autonomous roles of altered BCAA supply have been implicated in cancer progression. The critical proteins involved in BCAA uptake, transport, metabolism, etc. serve as potential therapeutic biomarkers in human cancers. Here, we summarize the potential anti-tumor mechanism of BCAA by exploring the chain reaction triggered by increased BCAA supply in the tumor.&lt;h4>Method&lt;/h4>A system-wide strategy was employed to provide a generic solution to establish the links between BCAA and cancer based on comprehensive omics, molecular exp</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2026-05-13T14:33:18.794Z</modification><creation>2025-02-19T03:26:45.296Z</creation></dates><accession>S-EPMC9950318</accession><cross_references><pubmed>36820928</pubmed><doi>10.1007/s12672-023-00634-1</doi></cross_references></HashMap>